Recent Event Highlights: Multiple Myeloma Research Foundation (MMRF) Mourns Loss of Geraldine Ferraro - Business Wire (press release), Geraldine Ferraro succumbs to multiple myeloma at age 75 - Zap2it.com (blog), Multiple Myeloma Video: Physical Activity Cuts Salt's Effect on Blood Pressure ... - Insidermedicine, Multiple Myeloma Genome Sequenced, Reveals New Therapeutic Targets - Medscape, Beacon BreakingNews - European Multiple Myeloma Researchers Issue Statement on ... - The Myeloma Beacon, Genome Map of Multiple Myeloma Offers Clues to Its Cause - BusinessWeek, and 142 more...
Created by dipity on Aug 10, 2009
Last updated: 03/26/11 at 12:00 PM
Multiple Myeloma has no followers yet. Be the first one to follow.
Multiple Myeloma Research Foundation (MMRF) Mourns Loss of Geraldine FerraroBusiness Wire (press release)(BUSINESS WIRE)--The Multiple Myeloma Research Foundation (MMRF) is deeply saddened by the loss of Geraldine Ferraro (1935-2011), a Member of the MMRF Honorary Board of Directors and a dear friend. Ferraro passed away this morning from complications ...and more »
msnbc.comGeraldine Ferraro succumbs to multiple myeloma at age 75Zap2it.com (blog)She passed away at Massachusetts General Hospital due to complications from multiple myeloma, a blood cancer she had dealt with for 12 years. A 1960 graduate of Fordham Law School, Ferraro was elected to the US House of Representatives in 1978. ...Political trailblazer Ferraro diesNEWS.com.auGeraldine Ferraro, First Woman VP Candidate, Dies at 75ABC NewsGeraldine Ferraro dies at 75PoliticoLos Angeles Times -Slate Magazine (blog) -People Magazineall 871 news articles »
JOEL STEPHEN McKIBLETimes Herald-RecordWe mourn the loss of our beloved Joel, who fought courageously against multiple myeloma. He passed away peacefully surrounded by his loving family. The son of the late Irving McKible and Agnes Marlieb McKible, Joel is survived by his wife, Rachel; ...
Longtime Edmond minister diesNewsOK.comDon Eugene Vinzant, longtime pulpit minister at Edmond Church of Christ, died March 10 after becoming ill with an advanced case of multiple myeloma. EDMOND — Don Eugene Vinzant, longtime pulpit minister at Edmond Church of Christ, died March 10 after ...
Multiple Myeloma Video: Physical Activity Cuts Salt's Effect on Blood Pressure ...InsidermedicineAnd finally, from New Jersey - Scientists have sequenced the multiple myeloma genome for the first time, according to a report published in Nature. Results of novel genome-sequencing techniques found genetic mutations that will lead to a better ...and more »
www.worldbulletin.netMultiple Myeloma Genome Sequenced, Reveals New Therapeutic TargetsMedscapeMarch 25, 2011 — The mammoth undertaking of sequencing the entire genomic multiple myeloma from tissue samples taken from 38 patients has shed light on the molecular mechanisms involved in this disease. It has also revealed some surprising potential ...Genome study reveals clues into blood cancer treatmentsCalgary HeraldInsights into cancer genome may lead to designer drugs for myelomaScientist Liveall 6 news articles »
Beacon BreakingNews - European Multiple Myeloma Researchers Issue Statement on ...The Myeloma BeaconA group of mainly European multiple myeloma researchers has issued a statement regarding the potential link between Revlimid and secondary cancer. According to the statement, the group initially met in Paris on February 23, 2011 at a meeting arranged ...
msnbc.comGenome Map of Multiple Myeloma Offers Clues to Its CauseBusinessWeekWEDNESDAY, March 23 (HealthDay News) -- The genome of the highly aggressive blood cancer multiple myeloma has been mapped by a team of North American scientists, who say their achievement will improve understanding of what causes the disease and may ...Multiple Myeloma Genome Sequencing Provides BreakthroughThirdAgeNew Clues Revealed For Multiple MyelomaRedOrbitResearchers sequence multiple myeloma genomeMilwaukee Journal Sentinel (blog)Mass High Tech -The Myeloma Beacon -Cordis Newsall 102 news articles »
Forbes (blog)A Cancer Patient's Quest Hits DNA Pay DirtForbes (blog)Now her fight with multiple myeloma has moved to a new front: DNA. Giusti was a 37-year-old marketing executive at Searle (now part of Pfizer) when she was diagnosed in 1996 with myeloma, a deadly blood and bone marrow cancer. ...and more »
...and analytical prowess and only a few studies to date have looked across more than one. The team of researchers studied 38 multiple myeloma patients, comparing the patients' normal genomes to the genomes from their malignant cells. With the whole cancer genome...
...in Cambridge and their collaborators, funded by the Multiple Myeloma Research Foundation, have sequenced the first multiple myeloma genome, a discovery they said could help drug developers better understand the disease and create new targets to treat it. “The...
Mass High Tech Business News
The Multiple Myeloma Research Foundation (MMRF) is working with patients, clinicians, and researchers to speed the development of targeted treatments for multiple myeloma. Watch this video of Amy Erwin, a multiple myeloma patient and Multiple Myeloma Research Consortium (MMRC) tissue donor, highlighting the importance of donating samples to the MMRF Tissue Bank.
NCCN Tweaks 2011 Multiple Myeloma GuidelinesMedscapeMarch 17, 2011 — The latest version of the National Comprehensive Cancer Network (NCCN) multiple myeloma guidelines include a few small changes to reflect recent advances in diagnosis and treatment. They were presented here at the NCCN 16th Annual ...and more »
Medtronic reports positive results from Kyphon Balloon Kyphoplasty studyTrading Markets (press release)It involved 134 patients with vertebral compression fractures who also had various types of cancer such as breast, lung, and prostate or had multiple myeloma and took place at 22 sites in the US, Europe, Australia and Canada. ...Spine Repair Effective in Cancer PatientsMedPage Todayall 24 news articles »
Health briefs, February 17Inland Valley Daily BulletinDr. Tanuja Bhandari, a radiation oncologist, will speak about the aspects of radiation in relation to multiple myeloma, which is a cancer of plasma cells. Bhandari is the featured speaker at a meeting hosted by the Inland Empire Multiple Myeloma ...and more »
Magic's Pat Williams talks about cancerMyFoxOrlando.com... said Pat Williams as he flashed a shirt bearing that slogan across the chest, just like Clark Kent reveals his Superman "S." The Orlando Magic's Senior Vice President Pat Williams spoke publicly about his recent diagnosis with multiple myeloma. ...Williams Ready to Attack Rare Blood DisorderThe Ledgerall 3 news articles »
Variations In Nervous System Genes May Put Multiple Myeloma Patients At Higher ...The Myeloma BeaconThalidomide (Thalomid) is one of the three novel agents that has significantly improved survival of multiple myeloma patients. However, the benefits of thalidomide are sometimes limited by the onset of several side effects, including peripheral ...and more »
Kansas City StarMagic SVP Diagnosed With Multiple MyelomaCharisma News OnlinePat Williams, senior vice president of the Orlando Magic, has been diagnosed with a blood and bone marrow cancer called multiple myeloma. The 70-year-old Orlando Magic legend, who has written more than 70 books, run dozens of marathons and raised 19 ...Denton: Pat Williams Diagnosed With Multiple MyelomaNBA.comMagic VP diagnosed with multiple myelomaWDBO RadioPat Williams: More about his blood diseaseOrlando SentinelUSA Today -Yahoo! Sportsall 462 news articles »
MyFox DetroitJames Giftos: Founder of National Coney IslandDetroit Free PressMr. Giftos, the founder of National Coney Island, a chain of metro Detroit restaurants, died Monday at St. John Hospital and Medical Center in Detroit after an extended battle with multiple myeloma. He was 72. "Hard work and attention to detail were ...National Coney Island founder James Giftos dies at 72WXYZNational Coney Island Founder James Giftos Dies at 72MyFox Detroitall 5 news articles »
Beacon NewsFlashes – February 14, 2011The Myeloma BeaconBafetinib May Prevent Bone Loss For Cancer Patients – A series of preclinical studies indicate that the drug bafetinib (INNO-406) inhibits bone deterioration in cancer patients who are at high risk for bone loss, including multiple myeloma patients. ...
...report provides an overview of the Multiple Myeloma therapeutic pipeline. This report provides information on the therapeutic development for Multiple Myeloma, complete with latest updates, and special features on late-stage and discontinued projects....
Hematologists Analyze Pipeline for Multiple Myeloma Therapeutics in New ReportBenzingaMedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled “Thought Leader Insight & Analysis: Multiple Myeloma,” designed to provide critical strategic insight for ...and more »
The Nebraska Medical Center's multiple myeloma specialists Edward Faber, MD and Julie Vose, MD, discuss the cancerous bone disease which affects certain white blood cells called plasma cells. Symptoms include holes in the bone and can lead to severe pain, fractures and weakness. Often these symptoms resemble other bone diseases. Test such as x-ray, magnetic resonance imaging (MRI) and bone marrow biopsy can be used to diagnose multiple myeloma. Treatment may include medications and surgical options to control the pain, repairing fractures, radiation therapy, chemotherapy and bone marrow transplantation or stem cell transplantation. For more information about The Nebraska Medical Center's myeloma program, visit www.nebraskamed.com or call 1-800-922-0000.
ADDING MULTIMEDIA Multiple Myeloma Research Foundation (MMRF) Partners with ...SunHerald.comThe Multiple Myeloma Research Foundation (MMRF), as the Benefiting Charity, is proud to be associated with two of the most iconic entities in all of New York, the NYRR and the Empire State Building. The mission of the MMRF, one of the nation's leading ...German wins race up Empire State BuildingMonsters and Critics.comWhy do the Empire State Run-Up? For the challengeUniversal Sports (blog)Germany's Thomas Dold Wins Empire State Building Run-Up (Again)SB Nation (blog)all 256 news articles »
Onyx multiple myeloma drug wins FDA fast-track statusBizjournals.comThe Food and Drug Administration granted Emeryville-based Onyx's (NASDAQ: ONXX) multiple myeloma treatment carfilzomib fast-track status, accelerating the agency's review of the potential blockbuster drug. Onyx initiated a rolling submission of its ...Onyx Gets Fast-Track Status From FDA For Blood-Cancer TreatmentWall Street JournalOnyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company ...PR Newswire (press release)Brean Murray Carret & Co. Reiterates Onyx Pharmaceuticals Buy Rating, $38 PT ...BenzingaRTT News -Daily Marketsall 37 news articles »
Multiple myeloma is a blood cancer affecting plasma cells—white blood cells that are a crucial part of the immune system and responsible for the production of antibodies. About 2100 new cases of multiple myeloma are diagnosed each year in Canada. In the past ten years, a number of new and effective drugs have been approved and are extending the survival of patients to an average of five years, but multiple myeloma is still incurable. The Princess Margaret is one of the top 5 multiple myeloma research centres worldwide, and one of four founding institutions of the Multiple Myeloma Research Consortium along with Harvard, the Mayo Clinic Cancer Center and the H. Lee Moffitt Cancer Center. Thanks to the personal generosity of David Bloom, a myeloma patient himself, financial support from two pharmaceutical companies, Celgene and Ortho Biotech, and the dedicated fundraising efforts of the 5K Multiple Myeloma Team, the hospital has received funding needed to establish a Chair position dedicated to leading multiple myeloma research. In 2010, this Chair was awarded to Dr. Donna Reece, the Director of PMH's Multiple Myeloma Program and an international expert in the disease. The strong myeloma clinical team, led by Dr. Donna Reece, works in close collaboration with a dedicated laboratory research team led by Dr. Suzanne Trudel to ensure that more promising new cancer drugs will be tested and moved as quickly as possible from the laboratory to patients. Better screening and tests ...
Paul Richardson, MD, Director of the Dana Farber Cancer Institute's Multiple Myeloma Center gives an overview of the current therapies for MM
Paul Richardson, MD Clinical Director of the Multiple Myeloma Center at Harvard's Dana-Farber Cancer Institute discusses The Lancet article by Cavo et al that was a RCT of Velcade plus Thalomid.
The Mayo Clinic's Dr. Keith Stewart, discusses the positive treatment landscape for patients with multiple myeloma. He reviews the options for newly diagnosed patients, those currently in treatment, and patients who are in need of a new therapy choice. He also discusses promising new medicine. Andrew is joined in this interview by 16-year myeloma survivor Jack Aiello.
The past few years have brought approvals for highly effective medicines to treat multiple myeloma. Now these drugs are being combined in powerful new ways and exciting new drugs are in late stage development. Dr. Dan Vogl, a myeloma specialist at Penn Medicine explains.
Dr. Ola Landgren, Head of the Multiple Myeloma Section in CCR's Medical Oncology Branch, takes you into his lab and clinic where he is studying two pre-myeloma conditions, patients with abnormal M-protein levels in their blood, and patients with smoldering multiple myeloma, a precursor disease that often transforms into multiple myeloma. He will show you how his natural history study of pre-myeloma patients will try to find treatments that can intervene earlier and keep the myeloma from progressing to a life-threatening disease. Learn more about Dr. Landgren's research at ccr.cancer.gov Learn more about Dr. Landgren's clinical trials at bethesdatrials.cancer.gov
August 17th, 2010 Good advice and hope
Dr Maria-Victoria Mateos discusses the data from a Phase III trial investigating various triplet and doublet regimens containing bortezomib in previously untreated elderly multiple myeloma patients. Dr Mateos concluded that VMP and VTP induction regimens showed comparable efficacy but differing toxicity profiles. Most important, in Dr Mateos' view, was the observation that these induction and maintenance regimens showed the ability to overcome the poor prognosis of high-risk elderly multiple myeloma patients. Dr Maria-Victoria Mateos - University Hospital of Salamanca, Spain, speaking at the 51st ASH Annual Meeting in New Orleans
I shaved my head to her support my mom with her fight against cancer. i raised over $4300 for the canadian cancer society and donations are still rolling in! if you wish to donate you can go to - convio.cancer.ca
Understanding Targeted Therapies for Multiple Myeloma - National Institutes of Health 2010 - Publication Q028 - National Cancer Institute. Describes targeted therapies for the treatment of multiple myeloma. Some of the questions answered by this educational tutorial for oncology health professionals include: What are targeted therapies; what do these new treatments target in multiple myeloma; which targeted cancer therapies are currently approved for myeloma by the Food and Drug Administration; and how can one find clinical trials that are evaluating targeted therapies for multiple myeloma.
MEDICENTER is a clinic specialized in attending patients with hematological (blood) and oncological (cancer) diseases. Medicenter is the only Stem Cell Transplant clinic in Guatemala that offers: •Treatments for benign and malignant diseases caused by different indications •State-of-the-art cryostorage technology. •Affordable treatment protocols for our patients and their families. Stem Cells can be obtained through three different sources: 1.Bone marrow 2.Umbilical cord blood 3.Peripheral blood. Stem Cells have the ability to transform in different cell types and contribute to tissues repair and recovery. Diseases that can be treated through Stem Cell Transplants: Cancer: Leukemia, lymphoma, multiple myeloma and solid tumors. Hematology: Congenital anemias. Nervous system: Brain paralysis, medullary lesions, multiple sclerosis, neuropathies, Parkinson and Alzheimer. Cardiology: Coronary ischemic disease, cardiomyopathies and congestive cardiac insufficiency. Diabetes: Treatment for diabetic foot ulcers. Organs insufficiency repair: Kidney and liver. Anti-age treatments. For more information about Stem Cell Transplantation for Multiple Myeloma learn more at: stem-cell-multiple-myeloma.angelsabroad.com
2010 Multiple Myeloma Research Foundation (MMRF) Corporate Video
DAY 5 - last round of chemo - 2 doses.....TOMORROW REST DAY, before umbilical cord cell infusion
PRE-DAY1 OF MOM(64) GOING INTO MD ANDERSON FOR 2ND TRANSPLANT...SHE DID TRANSPLANT 10 YEARS AGO, USING HER OWN CELLS. BUT ROUND 2 - DOING A UMBLICAL CORD CELL INFUSION AS WELL AS HER BROTHERS MATCHING CELL MARROW...FOR RESEARCH IN HOPE FOR CURE!...ITS A PROCESS AND WILL DOCUMENT IN VIDEO JOURNAL..mom was dignosed in 1997 and still fighting in 2010
Dr. Noopur Raje talks about treatment combinations for multiple myeloma and the hopes of transforming myeloma into a chronic illness.
Dr. Maria-Victoria Mateos talks about a new study from Spain revealing how lower doses of newer drugs can be used in the long-term to fight cancer with much lower side effects.
World-renowned physician and researcher, Dr. James R. Berenson discusses why clinical research is important in the fight to find a cure for multiple myeloma. Tomake an appointment or get a consult with Dr. Berenson, please visit our website: www.berensononcology.com. To learn more about Dr. Berenson's research or to make a donation to further myeloma research, visit The Institute for Myeloma and Bone Cancer Research at www.imbcr.org
A 60 second public service announcement about a new, free audio CD that allows you to listen to conversations between patients and doctors that find solutions to problems people face when living with multiple myeloma. Learn more at: www.canceradvocacy.org/toolbox
Kathy Giusti Tells the MMRF/MMRC Story at the Partnering for Cures Meeting Plenary. 12/2/2009. Kathy Giusti, Founder and CEO Multiple Myeloma Research Consortium.
January 10th, 2010 Results after 7 treatment of Revlimid Update from August 12th, 2009
More myeloma videos from ASH at ash.myeloma.org. Dr. Keith Stewart provides an update on novel agents for treatment of multiple myeloma from the 51st Annual Meeting of the American Society of Hematology.
Cancer Research Institute postdoctoral fellow Diego Acosta-Alvear, Ph.D., in the laboratory of Peter Walter, Ph.D., at the University of California, San Francisco - Howard Hughes Medical Institute in San Francisco, CA, is helping to conquer blood cancers by studying the regulation of the unfolded protein response in multiple myeloma. Multiple myeloma is an aggressive, incurable blood disease with poor survival rates and approximately 20000 cases per year in the United States. While therapeutic improvements have been made in the last decade, the disease remains incurable and the patients eventually succumb after becoming refractory to currently available treatments. Moreover, the biological cause(s) of the disease remain poorly understood. It is known that an essential mechanism called the unfolded protein response (UPR) is involved in protein synthesis for normal cellular functions, such as growth, communication, and survival. Therefore, a tight regulation of the UPR is a critical part of normal cell physiology. Accumulating evidence posits that some UPR components promote the survival of cancer cells and thus may contribute to myeloma progression. Dr. Acosta-Alvear is investigating the activation and regulation of UPR in multiple myeloma cells. He aims to establish molecular signatures associated with aberrant regulation of the UPR in multiple myeloma and to develop biochemical tools to manipulate the UPR to restrain tumor progression. By demonstrating that the UPR is ...